Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
China · Delayed Price · Currency is CNY 25.30
+1.16 (4.81%)
At close: Sep 30, 2026
SHA:688443 Revenue
Chongqing Genrix Biopharmaceutical had revenue of 85.86M CNY in the quarter ending June 30, 2026, with 240.21% growth. This brings the company's revenue in the last twelve months to 338.44M, up 348.41% year-over-year. In the year 2025, Chongqing Genrix Biopharmaceutical had annual revenue of 230.73M with 666.66% growth.
Revenue (ttm)
338.44M
Revenue Growth
+348.41%
P/S Ratio
27.41
Revenue / Employee
298.71K
Employees
1,133
Market Cap
9.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 230.73M | 200.63M | 666.66% |
| Dec 31, 2024 | 30.09M | 28.88M | 2,384.11% |
| Dec 31, 2023 | 1.21M | 736.26K | 154.92% |
| Dec 31, 2022 | 475.24K | -38.72M | -98.79% |
| Dec 31, 2021 | 39.19M | 38.10M | 3,502.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Pacific Shuanglin Bio-pharmacy | 2.48B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.03B |
| Aurisco Pharmaceutical | 1.70B |
| Jiangxi Fushine Pharmaceutical | 1.56B |
| Vcanbio Cell & Gene Engineering Corp., | 1.40B |
| Liaoning Chengda Biotechnology | 1.36B |
| Chengdu Easton Biopharmaceuticals | 1.34B |